Synovial fluid viscosity enhancement

Synovial fluid viscosity enhancement is not the name of a molecular target, receptor, enzyme, or defined biomolecule; rather, it describes a therapeutic objective or physiological effect intended to improve joint function by increasing the viscosity of synovial fluid. Synovial fluid viscosity is principally regulated by the concentration and molecular weight of hyaluronic acid (hyaluronan) and lubricin, both normal components of synovial fluid that provide lubrication, mechanical protection, and reduce cartilage wear[1][2][4][6]. Therapeutic approaches such as intra-articular injections of hyaluronic acid ("viscosupplementation") act to enhance synovial fluid viscosity, typically for treating joint disorders like osteoarthritis[2][7]. However, there is no single molecular entity or 'target' with the canonical name "Synovial fluid viscosity enhancement." Instead, the relevant biological targets would include molecules such as hyaluronic acid, lubricin, or their metabolic regulators. The phrase is best understood as a process or therapeutic category rather than a discrete molecular entity.